Literature DB >> 15532533

Dimethyl sulfoxide and ebselen prevent convulsions induced by 5-aminolevulinic acid.

Carlos André Prauchner1, Adriano Neujahr Agostini, Akemi Morimoto, Paula Rossini Augusti, Taís Cristina Unfer, Gilson Zeni, Carlos Fernando Mello, Tatiana Emanuelli.   

Abstract

We investigated whether intrastriatal (i.s.) administration of 5-aminolevulinic acid (ALA) induces oxidative damage and whether behavioral alterations induced by i.s. administration of ALA could be affected by antioxidants. Unilateral injection of ALA (6 micromol/striatum) increased (approximately 30%) thiobarbituric acid-reactive substances (TBARS), but did not affect striatal content of total thiol groups. ALA-induced body asymmetry was not prevented by pretreatment with ascorbic acid (100 mg/kg, s.c.), dimethyl sulfoxide (DMSO, 0.5 microl/striatum, i.s.) or ebselen (10 nmol/striatum, i.s.). ALA-induced convulsions were not prevented by ascorbic acid, but were partially prevented by DMSO and completely prevented by ebselen. Ebselen completely prevented the increase of striatal TBARS induced by ALA. Results obtained suggest the involvement of reactive species in ALA-induced convulsions and may be of value in understanding the physiopathology of neurological dysfunctions associated to ALA overload.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15532533     DOI: 10.1023/b:nere.0000042204.33161.9d

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  46 in total

1.  Ebselen blocks the quinolinic acid-induced production of thiobarbituric acid reactive species but does not prevent the behavioral alterations produced by intra-striatal quinolinic acid administration in the rat.

Authors:  Janine I Rossato; Gilson Zeni; Carlos F Mello; Maribel A Rubin; João B T Rocha
Journal:  Neurosci Lett       Date:  2002-02-01       Impact factor: 3.046

2.  delta-Aminolevulinic acid in plasma or whole blood as a sensitive indicator of lead effects, and its relation to the other heme-related parameters.

Authors:  T Sakai; Y Morita
Journal:  Int Arch Occup Environ Health       Date:  1996       Impact factor: 3.015

3.  The neuroprotective agent ebselen modifies NMDA receptor function via the redox modulatory site.

Authors:  G A Herin; S Du; E Aizenman
Journal:  J Neurochem       Date:  2001-09       Impact factor: 5.372

4.  Effects of 5-aminolevulinic acid on the glutamatergic neurotransmission.

Authors:  Tatiana Emanuelli; Fernanda W Pagel; Lisiane O Porciúncula; Diogo O Souza
Journal:  Neurochem Int       Date:  2003-01       Impact factor: 3.921

5.  Dimethyl sulfoxide suppresses NMDA- and AMPA-induced ion currents and calcium influx and protects against excitotoxic death in hippocampal neurons.

Authors:  C Lu; M P Mattson
Journal:  Exp Neurol       Date:  2001-07       Impact factor: 5.330

6.  Intrastriatal administration of 5-aminolevulinic acid induces convulsions and body asymmetry through glutamatergic mechanisms.

Authors:  T Emanuelli; C A Prauchner; J Dacanal; A Zeni; E C Reis; C F de Mello; D O de Souza
Journal:  Brain Res       Date:  2000-06-16       Impact factor: 3.252

7.  Exposure to ebselen changes glutamate uptake and release by rat brain synaptosomes.

Authors:  Cristina W Nogueira; Liane N Rotta; Gilson Zeni; Diogo O Souza; João B T Rocha
Journal:  Neurochem Res       Date:  2002-04       Impact factor: 3.996

Review 8.  Concept of activity-induced cell death in epilepsy: historical and contemporary perspectives.

Authors:  Brian S Meldrum
Journal:  Prog Brain Res       Date:  2002       Impact factor: 2.453

9.  Free radical generation in the brain precedes hyperbaric oxygen-induced convulsions.

Authors:  D Torbati; D F Church; J M Keller; W A Pryor
Journal:  Free Radic Biol Med       Date:  1992       Impact factor: 7.376

10.  Oxidative damage to ferritin by 5-aminolevulinic acid.

Authors:  Maria E M Rocha; Fernando Dutra; Brian Bandy; Regina L Baldini; Suely L Gomes; Adelaide Faljoni-Alário; Cleber W Liria; M Terêsa M Miranda; Etelvino J H Bechara
Journal:  Arch Biochem Biophys       Date:  2003-01-15       Impact factor: 4.013

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.